Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone805-562-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$68.13 million
Profitability
Miscellaneous
Employees259
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Sientra (NASDAQ:SIEN) Frequently Asked Questions
What is Sientra's stock symbol?
Sientra trades on the NASDAQ under the ticker symbol "SIEN."
How were Sientra's earnings last quarter?
Sientra Inc (NASDAQ:SIEN) posted its quarterly earnings data on Thursday, August, 8th. The medical instruments supplier reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.50. The medical instruments supplier earned $20.53 million during the quarter, compared to analyst estimates of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. Sientra's revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.73) EPS. View Sientra's Earnings History.
When is Sientra's next earnings date?
What guidance has Sientra issued on next quarter's earnings?
Sientra issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $79-83 million, compared to the consensus revenue estimate of $81.13 million.
What price target have analysts set for SIEN?
8 equities research analysts have issued twelve-month price targets for Sientra's shares. Their forecasts range from $10.00 to $27.00. On average, they anticipate Sientra's stock price to reach $15.75 in the next year. This suggests a possible upside of 154.0% from the stock's current price. View Analyst Price Targets for Sientra.
What is the consensus analysts' recommendation for Sientra?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sientra.
Has Sientra been receiving favorable news coverage?
Media coverage about SIEN stock has trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sientra earned a news impact score of -2.6 on InfoTrie's scale. They also assigned news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Sientra.
Are investors shorting Sientra?
Sientra saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,200,000 shares, an increase of 10.3% from the August 30th total of 2,900,000 shares. Based on an average daily trading volume, of 969,200 shares, the short-interest ratio is currently 3.3 days. Approximately 7.5% of the shares of the stock are short sold. View Sientra's Current Options Chain.
Who are some of Sientra's key competitors?
Some companies that are related to Sientra include Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Histogenics (HSGX), ConforMIS (CFMS), Lakeland Industries (LAKE), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), Precision Therapeutics (POAI), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Bionik Laboratories (BNKL), Allied Healthcare Products (AHPI) and Ocugen (OCGN).
What other stocks do shareholders of Sientra own?
Who are Sientra's key executives?
Sientra's management team includes the folowing people:
- Mr. Jeffrey M. Nugent, Chairman & CEO (Age 72)
- Mr. Charles Huiner, COO and Sr. VP of Corp. Devel. & Strategy (Age 48)
- Mr. Keith J. Sullivan, Director & Advisor to MiraDry Bus. (Age 61)
- Mr. Paul Sean Little, CFO, Sr. VP & Treasurer (Age 54)
- Ms. Deborah Bettencourt, VP of Customer Experience & Corp. Admin.
How do I buy shares of Sientra?
Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sientra's stock price today?
One share of SIEN stock can currently be purchased for approximately $6.20.
How big of a company is Sientra?
Sientra has a market capitalization of $305.60 million and generates $68.13 million in revenue each year. The medical instruments supplier earns $-82,630,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Sientra employs 259 workers across the globe.View Additional Information About Sientra.
What is Sientra's official website?
How can I contact Sientra?
Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at 805-562-3500 or via email at [email protected]
MarketBeat Community Rating for Sientra (NASDAQ SIEN)
MarketBeat's community ratings are surveys of what our community members think about Sientra and other stocks. Vote "Outperform" if you believe SIEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SIEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
